An interventional study of adapted vaping cessation intervention in E Cigarette Use, sponsored by Veterans Medical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.
Among the 288 studies in Vaping with a site in United States, this one is the 216th largest by planned enrollment of the 258 interventional ones that give a count, is one of 31 that started in 2024, is one of 206 with no phase, reaches primary completion later than 9 of the 73 other live ones, and was the 206th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
288 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 79 across 324 interventional studies indexed under Vaping.
Median enrollment 71 across the 258 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 288 have an industry lead sponsor. The 10 most frequent:
Veterans Medical Research Foundation is the lead sponsor of 43 studies on the registry; 9 are open to participants now.
Veterans Medical Research Foundation has 1 study filed under Vaping — fewer than ten, so there is no comparison to draw.
31 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 31 to your calendar (.ics) → With an account.
Among the 288 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this proposal is to adapt an evidence-based combustible tobacco counseling intervention following an evidence-based process to include e-cigarette use and update its components for emerging adults (EA).
Use of electronic nicotine products (ENDS) has increased dramatically especially among young adults (EA- aged 18-30) and has been found to lead to immediate harmful health effects and increased addiction to combustible cigarette use. To date no research-tested interventions have been developed for helping people stop use of electronic nicotine products. Emerging adulthood is a developmental period that can lead to adoption of health risk behaviors.
This proposal aims to address nicotine addiction by adapting an evidence-based counseling cessation intervention developed by the American Cancer Society (ACS) for a general population of combustible tobacco smokers, but found to be effective in EA. We will test two methods of providing counseling to participants: video telehealth or telephone. Primary outcome: Compared to self-help guide only, at 3 month follow-up, we hypothesize that participants in either counseling arm will have higher rates as compared to self-help only control of 7-day abstinence from using any nicotine product.
This study fills a critical gap in ENDS research and will provide a model for further research into all-nicotine cessation in this vulnerable population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants assigned to this group will receive the adapted intervention by telephone.
Behavioral: adapted vaping cessation intervention
Participants assigned to this group will receive the adapted intervention by video telehealth.
Behavioral: adapted vaping cessation intervention
Behavioral intervention for vaping cessation
e-cigarette use frequency
number of days using e-cigarettes in the past 7 days at the time of assessment
Time frame: end of treatment (8 weeks post-baseline) and 30 days thereafter
e-cigarette use quantity
number of e-cigarette uses per day
Time frame: end of treatment (8 weeks post-baseline) and 30 days thereafter
Client Satisfaction Questionnaire (CSQ-8)
Participant satisfaction ratings; higher scores indicate greater satisfaction with the intervention
Time frame: end of treatment (8 weeks post-baseline) and 30 days thereafter
Plan to share: No — Sample size is sufficiently small that sharing could threaten confidentiality.
Started Jan 2024 (actual). Primary completion is estimated for Jun 2026, 29 months after the start.
Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 29 months is above that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Veterans Medical Research Foundation